中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.012 seconds)

    METHODS AND COMPOSITIONS FOR PREPARING CAPPED RNA
    1.
    发明申请
    METHODS AND COMPOSITIONS FOR PREPARING CAPPED RNA 审中-公开
    制备CAPPED RNA的方法和组合物

    公开(公告)号：WO2006004648A1

    公开(公告)日：2006-01-12

    申请号：PCT/US2005/022710

    申请日：2005-06-28

    Applicant: AMBION, INC. ,  LABOURIER, Emmanuel ,  PASLOSKE, Brittan, L.

    Inventor： LABOURIER, Emmanuel ,  PASLOSKE, Brittan, L.

    IPC: C12P19/34

    CPC classification number: C12N15/79

    Abstract: The present invention concerns methods and compositions for increasing the yield of capped and full-length RNA transcripts produced in in vitro transcription reactions. Such methods and compositions can be used for cost-efficient, large-scale production of capped full-­length RNA transcripts that can be subsequently translated. Methods and compositions involve reaction conditions that promote such production and include the implementation of fed-batch introduction of GTP, which competes with a cap analog.

    Abstract translation: 本发明涉及用于增加在中产生的封端和全长RNA转录物的产量的方法和组合物

    miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
    2.
    发明申请
    miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS 审中-公开
    癌症患者淋巴结中差异表达的miRNA

    公开(公告)号：WO2009100430A3

    公开(公告)日：2009-10-01

    申请号：PCT/US2009033556

    申请日：2009-02-09

    Applicant: ASURAGEN INC ,  BEAUDENON SYLVIE ,  ELIZONDO LAURA ,  DOLESHAL MARTINA ,  BROWN DAVID ,  LABOURIER EMMANUEL

    Inventor： BEAUDENON SYLVIE ,  ELIZONDO LAURA ,  DOLESHAL MARTINA ,  BROWN DAVID ,  LABOURIER EMMANUEL

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12N15/111 ,  C12N2310/141 ,  C12N2320/10 ,  C12N2330/10 ,  C12Q2600/112 ,  C12Q2600/178

    Abstract: The present invention provides diagnostics and/or prognostic methods by identifying miRNAs that are differentially expressed or mis-regulated in various states of diseased, normal, cancerous, and/or abnormal tissues, including but not limited to cervix, skin, colon, breast, bladder, esophagus, liver, ovary, prostate, lung, pancreas, thyroid, kidney, stomach, testicle, uterus, spleen, tongue, brain, thymus, trachea and/or small intestine. In certain apsects, differential miRNA expression is initially determined by comparing miRNA expression between a normal tissue and cancer negative lymph node (LNneg), a normal tissue and a cancer positive lymph node (LNpos), a cancerous tissue and LNneg and/or LNpos, LNneg and LNpos. The methods of the invention are used to identify the presence or absence of non-lymphoid cells from other organs or tissues, and/or metastatic cancer cells present in lymph nodes.

    Abstract translation: 本发明通过鉴定在患病，正常，癌和/或异常组织的各种状态中差异表达或错误调节的miRNA，所述组织包括但不限于宫颈，皮肤，结肠，乳房， 膀胱，食道，肝脏，卵巢，前列腺，肺，胰腺，甲状腺，肾，胃，睾丸，子宫，脾，舌，脑，胸腺，气管和/或小肠。 在某些方面，首先通过比较正常组织和癌症阴性淋巴结（LNneg），正常组织和癌症阳性淋巴结（LNpos），癌性组织和LNneg和/或LNpos之间的miRNA表达来确定差异miRNA表达， LNneg和LNpos。 本发明的方法用于鉴定存在于或不存在来自其他器官或组织，和/或存在于淋巴结中的转移性癌细胞的非淋巴细胞。

    NUCLEIC ACID QUANTITATION METHODS
    3.
    发明申请
    NUCLEIC ACID QUANTITATION METHODS 审中-公开
    核酸定量方法

    公开(公告)号：WO2008137466A3

    公开(公告)日：2009-03-12

    申请号：PCT/US2008062072

    申请日：2008-04-30

    Applicant: ASURAGEN INC ,  LATHAM GARY J ,  PELTIER HEIDI J ,  KEMPPAINEN JON ,  DAVISON TIMOTHY S ,  LABOURIER EMMANUEL ,  BROWN DAVID ,  WINKLER MATTHEW

    Inventor： LATHAM GARY J ,  PELTIER HEIDI J ,  KEMPPAINEN JON ,  DAVISON TIMOTHY S ,  LABOURIER EMMANUEL ,  BROWN DAVID ,  WINKLER MATTHEW

    IPC: C12Q1/68

    CPC classification number: C12Q1/6851 ,  Y10T436/143333 ,  C12Q2545/107

    Abstract: The invention relates to a method of determining the amount of a target nucleic acid sequence in a sample, the method comprising: obtaining multiple distinguishable amplicons of the target nucleic acid sequence, each comprising a distinguishing tag and a target portion; amplifying the amplicons in a single reaction volume; and detecting nucleic acids amplified from the amplicons. Detection of the distinguishable amplicons can be varied in each of the steps of the method, which expands the dynamic range of the nucleic acid quantification methods and improves the reliability and accuracy of the methods.

    Abstract translation: 本发明涉及一种测定样品中靶核酸序列量的方法，所述方法包括：获得靶核酸序列的多个可区分扩增子，每个扩增子包含鉴别标签和目标部分; 在单个反应体积中扩增扩增子; 并检测从扩增子扩增的核酸。 可区分扩增子的检测可以在该方法的每个步骤中变化，这扩大了核酸定量方法的动态范围，并提高了方法的可靠性和准确性。

    miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
    10.
    发明申请
    miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS 审中-公开
    miRNA在癌症患者的淋巴结中明显不同

    公开(公告)号：WO2009100430A2

    公开(公告)日：2009-08-13

    申请号：PCT/US2009/033556

    申请日：2009-02-09

    Applicant: ASURAGEN, INC ,  BEAUDENON, Sylvie ,  ELIZONDO, Laura ,  DOLESHAL, Martina ,  BROWN, David ,  LABOURIER, Emmanuel

    Inventor： BEAUDENON, Sylvie ,  ELIZONDO, Laura ,  DOLESHAL, Martina ,  BROWN, David ,  LABOURIER, Emmanuel

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12N15/111 ,  C12N2310/141 ,  C12N2320/10 ,  C12N2330/10 ,  C12Q2600/112 ,  C12Q2600/178

    Abstract: The present invention provides diagnostics and/or prognostic methods by identifying miRNAs that are differentially expressed or mis-regulated in various states of diseased, normal, cancerous, and/or abnormal tissues, including but not limited to cervix, skin, colon, breast, bladder, esophagus, liver, ovary, prostate, lung, pancreas, thyroid, kidney, stomach, testicle, uterus, spleen, tongue, brain, thymus, trachea and/or small intestine. In certain apsects, differential miRNA expression is initially determined by comparing miRNA expression between a normal tissue and cancer negative lymph node (LNneg), a normal tissue and a cancer positive lymph node (LNpos), a cancerous tissue and LNneg and/or LNpos, LNneg and LNpos. The methods of the invention are used to identify the presence or absence of non-lymphoid cells from other organs or tissues, and/or metastatic cancer cells present in lymph nodes.

    Abstract translation: 本发明通过鉴定在患病，正常，癌性和/或异常组织的各种状态中差异表达或错误调节的miRNA来提供诊断和/或预后方法，包括但不限于子宫颈，皮肤，结肠，乳房， 膀胱，食管，肝，卵巢，前列腺，肺，胰腺，甲状腺，肾，胃，睾丸，子宫，脾，舌，脑，胸腺，气管和/或小肠。 在某些apsects中，差异miRNA表达最初通过比较正常组织和癌阴性淋巴结（LNneg），正常组织和癌淋巴结（LNpos），癌组织和LNneg和/或LNpos之间的miRNA表达来确定， LNneg和LNpos。 本发明的方法用于鉴定存在于淋巴结中的其它器官或组织和/或转移性癌细胞的非淋巴细胞的存在或不存在。

Patent Agency Ranking